Compugen (NASDAQ:CGEN) Announces Earnings Results, Misses Estimates By $0.20 EPS

Compugen (NASDAQ:CGEN) issued its quarterly earnings data on Tuesday. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.20), Zacks reports. Compugen had a return on equity of 2.61% and a net margin of 2.67%. The company had revenue of $17.13 million during the quarter, compared to analysts’ expectations of $17.67 million. During the same quarter last year, the business earned ($0.11) earnings per share.

Compugen Price Performance

NASDAQ CGEN traded up $0.01 during trading hours on Wednesday, reaching $1.61. 230,524 shares of the company’s stock traded hands, compared to its average volume of 406,532. The firm has a market cap of $143.68 million, a PE ratio of 80.50 and a beta of 2.64. Compugen has a 52-week low of $0.55 and a 52-week high of $3.03. The firm has a 50-day simple moving average of $1.77 and a 200 day simple moving average of $1.88.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.